Results 181 to 190 of about 1,906,742 (351)

The expression of tyrosine kinase and threonine promotes the progression of lung adenocarcinoma and is linked to a negative prognosis. [PDF]

Medicine (Baltimore)
Zhu X, Li S, Ye L.
europepmc   +1 more source

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

New England Journal of Medicine, 2014
J. Woyach, R. Furman, Ta-Ming Liu, H. Ozer, M. Zapatka, A. Ruppert, L. Xue, Daniel Li, S. Steggerda, M. Versele, S. Dave, Jenny Zhang, A. S. Yilmaz, S. Jaglowski, K. Blum, A. Lozanski, G. Lozanski, D. James, J. Barrientos, P. Lichter, S. Stilgenbauer, J. Buggy, B. Chang, A. Johnson, J. Byrd   +24 more
semanticscholar   +1 more source

Real‐Time Visualization of Isoform‐Specific RAF‐KRAS Interactions in Living Cells Using FRET‐BRET Hybrid Biosensors

Advanced Science, EarlyView.
Hybrid FRET–BRET biosensors were developed to monitor RAF–KRAS interactions in living cells. These sensors enable real‐time visualization of interaction dynamics, quantitative spectral analysis, and validation of mutation‐selective inhibitors, providing a versatile platform for probing KRAS regulation and therapeutic responses. ABSTRACT The RAS–RAF–MEK–
Jeong‐Min Go, Dahee Lee, Minji Kim, Kiseok Han, Gyuho Choi, ChanHui Song, Sanghyun Ahn, Yerim Lee, Jinyoung Lee, Yingxiao Wang, Jung‐Soo Suh, Hwayoung Yun, Tae‐Jin Kim   +12 more
wiley   +1 more source

Drug-drug interactions in targeted cancer therapies: a focus on tyrosine kinase inhibitors. [PDF]

Expert Rev Clin Pharmacol
Stromatt JC, Chowdhury AT, Huang KM, Hu S, Sparreboom A, Baker SD, Eisenmann ED.   +6 more
europepmc   +1 more source

Supplementary Figure S8 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer

Tatsuya Ogimoto, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Masatoshi Yamazoe, Kentaro Hashimoto, Hiroshi Yoshida, Kazutaka Hosoya, Hitomi Ajimizu, Takashi Nomizo, Hironori Yoshida, Masatsugu Hamaji, Toshi Menju, Akihiko Yoshizawa, Hiroshi Date, Toyohiro Hirai   +15 more
openalex   +1 more source

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

New England Journal of Medicine, 2003
J. Cools, D. DeAngelo, J. Gotlib, E. Stover, R. Legare, J. Cortes, J. Kutok, Jennifer Hayes Clark, I. Galinsky, J. Griffin, N. Cross, A. Tefferi, J. Malone, R. Alam, S. Schrier, J. Schmid, M. Rose, P. Vandenberghe, G. Verhoef, M. Boogaerts, I. Wlodarska, H. Kantarjian, P. Marynen, S. Coutre, R. Stone, D. Gilliland   +25 more
semanticscholar   +1 more source

3D Bioprinted Fat‐Myocardium Model Unravels the Role of Adipocyte Hypertrophy in Atrial Dysfunction

Advanced Science, EarlyView.
A human‐derived 3D bioprinted fat–myocardium model is developed to investigate how adipocyte hypertrophy drives atrial dysfunction in obesity. Palmitate‐induced adipocyte hypertrophy promotes adipose dysfunction that impairs atrial cardiomyocyte metabolism and electrophysiology through both paracrine and direct interactions. This platform recapitulates
Lara Ece Celebi, Pinar Zorlutuna
wiley   +1 more source

Bibliometric analysis and recent trends on tyrosine kinase inhibitors in leukemia. [PDF]

Discov Oncol
Cheng J, Fang Y, Dong J, Zhang X, Yuan Y, Dang X.   +5 more
europepmc   +1 more source

Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.

American Journal of Obstetrics and Gynecology, 2016
F. Brownfoot, R. Hastie, N. Hannan, P. Cannon, L. Tuohey, L. Parry, Sevvandi N. Senadheera, S. Illanes, T. Kaitu’u-Lino, S. Tong   +9 more
semanticscholar   +1 more source

Tyrosine Kinases in Cancer.

Biomarker insights, 2015
Blau, Olga, Afanasyev, Boris, Blau, Igor Wolfgang   +2 more
openaire   +2 more sources